With the rapid development of GLP-1 drugs in the fields of diabetes and obesity, injection pens, as their main delivery method, have also attracted great attention from the market. An injection pen is a syringe that can accurately control the dose and speed. It has the advantages of easy use, safety and reliability, and independent medical treatment. It is suitable for patients who take medicine for a long time. At present, the global injection pen market has reached tens of billions of dollars and is expected to continue to grow in the future.
However, the injection pen market also faces fierce competition and technical barriers. Currently, the global injection pen market is dominated by multinational pharmaceutical companies such as Novo Nordisk, Eli Lilly, and Sanofi, with domestic companies accounting for only a minority. This is mainly because injection pens involve a number of core technologies and patents and require high-level R&D capabilities and production equipment. In addition, the injection pen also needs to be matched and verified with downstream drugs, and a stable cooperative relationship needs to be established with pharmaceutical companies.
However, with the increase in domestic drug innovation and market demand, domestic injection pens have also ushered in new opportunities. On the one hand, domestic pharmaceutical companies have made breakthrough progress in the field of GLP-1 drugs. For example, products such as Hisun Pharmaceutical’s Heglitide and China Resources Shuanghor’s Shuangglitide have been launched or are about to be launched. These are domestically produced products. Injection pens provide more downstream needs. On the other hand, domestic injection pen companies have also made progress in technological innovation and cost control. For example, Hanerxi Medical, YPS Medical and other companies have successfully developed cost-effective injection pen products that meet international standards and have cooperated with many companies. Pharmaceutical companies have established cooperative relationships.
The injection pen market is an area full of potential and challenges. With the rapid development of GLP-1 drugs and the expansion of the domestic market, domestic injection pens are expected to accelerate the substitution of imported products and achieve industrial upgrading and value enhancement.
In terms of domestic opportunities, the downstream blue ocean market opens up upstream injection pen production, OEM, and equipment opportunities, and the downstream + upstream opens up opportunities for import substitution of injection pens. At the same time, domestic centralized procurement requires cost reduction for injection pens, further forcing local substitution.
